Up to date, several first generation TRAIL receptor-targeting agonists including recombinant soluble TRAIL (rsTRAIL), agonistic monoclonal antibody against TRAIL-R1 (DR4) or TRAIL-R2 (DR5) have been developed for cancer therapy in early phase clinical trials (phase I/II) 5. This evidence concerns the gene TNFRSF10B and cancer.